

RAID-CRC



THE PROBLEM

Colonoscopy, the gold standard for CRC diagnosis, is expensive and hazardous.

Existing non-invasive tools for CRC screening, such as the fecal immunochemical test (FIT), have low sensitivity and reduced predictability, leading to a high rate of false positive results and a large number of unnecessary colonoscopies.

THE SOLUTION

Faster, reliable, cheaper medical diagnosis for CRC.

RAID-CRC (Risk Assessment Intestinal Disease for Colorectal Cancer) is a patented, non-invasive tool for CRC screening that allows CRC early detection in just 2h and with a cost non exceeding 12€ per sample.

THE PRODUCT

RAID-CRC is the first non-invasive technology for CRC screening based on detecting a specific bacterial signature in the fecal sample.

This tool allows reliable and fact CRC early detection, increasing sensitivity for precancerous lesions to 59% and reducing up to 32% of unnecessary colonoscopies.

MILESTONES

Founded
2014

Proof of Concept
2015
PCT Application

Analytic Validation
2016


Patent Protection
2017

Clinical Validation
2018

CE Mark/ Market Launch
2019-2020

POTENTIAL MARKET

World Population aged 50-75: **1.5 Billion**
Source: [United Nations DESA](#)



FUNDING GOALS



KEY METRICS

10€	Price/kit
80%	Potential penetration rate
500k€	Projected Gross Annual Revenue in 2018
2.3€ Billion/Year	Potential Market
150%	Sales Increase for the RAID-CRC test in 2019
4M€	Current Valuation in the Market



FOUNDERS



Mariona Serra
CEO



Xavier Aldeguer
Medical Director



Jesús García-Gil
CRO



Jaume Amat
Strategic Advisor



www.cimti.cat |
info@cimti.cat

PROMOTER



WITH THE SUPPORT OF

